← Eichor
Condition: Monoclonal Gammopathy Of Renal Significance Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Monoclonal Gammopathy Of Renal Significance

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

The Effect of Daratumumab in Patients with Monoclonal Gammopathy of Renal Significance (MGRS) in Finland
Phase 2 · 1 location(s) · Helsinki University Central Hospital · NCT06889948A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH
Phase N/A · 1 location(s) · Peking University First Hospital · NCT05283993A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of
Phase 2 · 11 location(s) · Memorial Sloan Kettering Cancer Center · NCT06083922Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD
Phase 2 · 3 location(s) · Peking University People's Hospital · NCT06418477National Registry of Rare Kidney Diseases
Phase N/A · 1 location(s) · UK Kidney Association · NCT06065852
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.